GeneHealth - Your precision medicine

Cholestasis

Disease Details

Family Health Simplified

Buy Membership

Description: Cholestasis is a condition where bile flow from the liver is reduced or blocked, leading to an accumulation of bile acids in the liver and bloodstream.
Type: Cholestasis can have multiple types, including intrahepatic cholestasis (originating within the liver) and extrahepatic cholestasis (originating outside the liver). Some forms of cholestasis, like Progressive Familial Intrahepatic Cholestasis (PFIC), are inherited and typically follow an autosomal recessive pattern of genetic transmission.
Signs And Symptoms: The signs and symptoms of cholestasis vary according to the cause. In case of sudden onset, the disease is likely to be acute, while the gradual appearance of symptoms suggests chronic pathology. In many cases, patients may experience pain in the abdominal area. Localization of pain to the upper right quadrant can be indicative of cholecystitis or choledocholithiasis, which can progress to cholestasis.Pruritus or itching is often present in many patients with cholestasis. Patients may present with visible scratch marks as a result of scratching. Pruritus is often misdiagnosed as a dermatological condition, especially in patients that do not have jaundice as an accompanying symptom. In a typical day, pruritus worsens as the day progresses, particularly during the evening time. Overnight, pruritus dramatically improves. This cycle can be attributed to an increase in the concentration of biliary elements during the day due to food consumption, and a decline at night. Pruritus is mostly localized to the limbs, but can also be more generalized. The efficacy of naltrexone for cholestatic pruritus suggests involvement of the endogenous opioid system.
Many patients may experience jaundice as a result of cholestasis. This is usually evident after physical examination as yellow pigment deposits on the skin, in the oral mucosa, or conjunctiva. Jaundice is an uncommon occurrence in intrahepatic (metabolic) cholestasis, but is common in obstructive cholestasis. The majority of patients with chronic cholestasis also experience fatigue. This is likely a result of defects in the corticotrophin hormone axis or other abnormalities with neurotransmission. Some patients may also have xanthomas, which are fat deposits that accumulate below the skin. These usually appear waxy and yellow, predominantly around the eyes and joints. This condition results from an accumulation of lipids within the blood. If gallstones prevent bile flowing from the pancreas to the small intestine, it can lead to gallstone pancreatitis. Physical symptoms include nausea, vomiting, and abdominal pain.
Bile is required for the absorption of fat-soluble vitamins. As such, patients with cholestasis may present with a deficiency in vitamins A, D, E, or K due to a decline in bile flow. Patients with cholestasis may also experience pale stool and dark urine.
Prognosis: The prognosis for cholestasis varies depending on the underlying cause. If the cause is identified and effectively treated, the prognosis is generally favorable. However, if left untreated, cholestasis can lead to complications such as liver damage, cirrhosis, and liver failure. Early diagnosis and management are crucial for improving outcomes.
Onset: Cholestasis can have an insidious or acute onset, depending on the underlying cause. Symptoms often include jaundice, pruritus (itching), dark urine, and pale stools.
Prevalence: Cholestasis is a condition characterized by impaired bile flow from the liver. The prevalence of cholestasis can vary depending on the underlying cause and population studied. Neonatal cholestasis occurs in approximately 1 in every 2,500 live births. In adults, the prevalence can differ widely based on factors such as the presence of liver diseases, medication use, and other health conditions. Chronic cholestatic liver diseases, like primary biliary cholangitis (PBC), have a prevalence of around 1 to 40 cases per 100,000 people globally.
Epidemiology: Cholestasis is a condition characterized by impaired bile flow from the liver. Here's a summary of its epidemiology:

- **Prevalence and Incidence**: The prevalence and incidence of cholestasis vary according to its type and underlying causes. It is less common in the general population but can be more frequent among those with certain risk factors.

- **Gender Differences**: Some forms of cholestasis, such as intrahepatic cholestasis of pregnancy, occur predominantly in women, especially during pregnancy. Other forms can affect both genders equally.

- **Age Distribution**: Cholestasis can occur at any age, but the age distribution depends on the type. For example, primary biliary cholangitis usually affects middle-aged women, while neonatal cholestasis is seen in newborns.

- **Geographical Variations**: The incidence may vary geographically depending on genetic predispositions, environmental factors, and healthcare practices. For instance, primary biliary cholangitis and primary sclerosing cholangitis have higher prevalence rates in North America and Northern Europe.

- **Risk Factors**: Common risk factors include liver diseases (like hepatitis or cirrhosis), certain medications, genetic predispositions, and conditions such as sepsis or biliary tract obstructions.

Accurate epidemiological data often require stratification by specific types of cholestasis and underlying etiologies.
Intractability: Cholestasis is not inherently intractable. The prognosis and potential for management or resolution depend on its underlying cause. Some forms of cholestasis may be effectively treated if the cause is identified and addressed, such as with bile duct obstructions or certain drug-induced cases. However, chronic or severe cases, especially those associated with liver disease or genetic conditions, may be more challenging to manage and could require long-term treatment strategies.
Disease Severity: Cholestasis is a condition where bile flow from the liver is reduced or blocked. The severity of cholestasis can vary widely, ranging from mild to severe. In mild cases, it may cause symptoms like itching and fatigue, while severe cases can lead to complications such as jaundice, liver damage, or even liver failure if left untreated. The severity often depends on the underlying cause of the cholestasis and how promptly it is diagnosed and managed.
Healthcare Professionals: Disease Ontology ID - DOID:13580
Pathophysiology: Cholestasis is a condition characterized by the impairment of bile flow. The pathophysiology involves either intrahepatic or extrahepatic factors:

- **Intrahepatic cholestasis** occurs due to liver cell dysfunction or impaired bile secretion within the liver. Causes include viral hepatitis, alcoholic liver disease, drug-induced liver injury, and genetic disorders like progressive familial intrahepatic cholestasis.

- **Extrahepatic cholestasis** results from the obstruction of bile ducts outside the liver. Common causes include gallstones, tumors, strictures, and pancreatitis.

In both types, the impaired bile flow leads to the accumulation of bile acids in the liver and bloodstream, causing symptoms like jaundice, itching (pruritus), and dark urine. Chronic cholestasis can lead to liver damage and complications such as fat-soluble vitamin deficiencies and osteoporosis.
Carrier Status: Cholestasis is a condition where bile flow from the liver is reduced or blocked. It is not typically characterized by a carrier status since it is not an infectious disease. The etiology can be due to various factors, including genetic mutations, liver diseases, bile duct obstructions, or certain medications.
Mechanism: Bile is secreted by the liver to aid in the digestion of fats. Bile formation begins in bile canaliculi that form between two adjacent surfaces of liver cells (hepatocytes) similar to the terminal branches of a tree. The canaliculi join each other to form larger and larger structures, sometimes referred to as the canals of Hering, which themselves join to form small bile ductules that have an epithelial surface. The ductules join to form bile ducts that eventually form either the right main hepatic duct that drains the right lobe of the liver, or the left main hepatic duct draining the left lobe of the liver. The two ducts join to form the common hepatic duct, which in turn joins the cystic duct from the gall bladder, to give the common bile duct. This duct then enters the duodenum at the ampulla of Vater. In cholestasis, bile accumulates in the hepatic parenchyma.One of the most common causes of extrahepatic, or obstructive cholestasis, is biliary obstruction. This is better known as choledocholithiasis where gallstones become stuck in the common bile duct.
Treatment: Cholestasis treatment focuses on managing symptoms and addressing the underlying cause of bile flow obstruction. Approaches can include:

1. **Medication**:
- Ursodeoxycholic acid to improve bile flow.
- Cholestyramine for itching relief.
- Rifampicin or opioid antagonists for severe itching.
- Vitamin supplementation (A, D, E, K) due to malabsorption.

2. **Non-Medical Interventions**:
- Dietary modifications, such as low-fat diets.
- Avoiding alcohol and hepatotoxic drugs.

3. **Procedures and Surgery**:
- Endoscopic retrograde cholangiopancreatography (ERCP) to remove bile duct obstructions.
- Surgery to remove gallstones or tumors causing obstruction.
- Liver transplant in severe, irreversible cases of liver damage.

4. **Supportive Care**:
- Monitoring and managing associated conditions such as infections or liver failure.
Compassionate Use Treatment: For cholestasis, compassionate use treatments, off-label, or experimental treatments may include:

1. **Ursodeoxycholic Acid (UDCA):** While commonly used for primary biliary cholangitis, it may be considered off-label for other cholestatic conditions to improve bile flow and liver function.

2. **Obeticholic Acid:** Originally approved for primary biliary cholangitis, it might be used off-label or in clinical trials for other types of cholestasis.

3. **Farnesoid X Receptor (FXR) agonists:** These are experimental treatments aimed at regulating bile acid synthesis and improving liver function.

4. **Antipruritics:** Medications like rifampin, naltrexone, or sertraline may be used off-label for symptomatic relief of pruritus in cholestasis.

5. **Liver Transplantation:** In severe cases where other treatments fail, liver transplantation might be considered under compassionate use scenarios.

It's essential to discuss these options with a healthcare provider to understand the potential benefits and risks.
Lifestyle Recommendations: Cholestasis is a condition where bile flow from the liver is reduced or blocked. Lifestyle recommendations for those with cholestasis include:

1. **Dietary Changes**:
- Eat a low-fat diet to reduce the workload on the liver.
- Increase intake of fruits and vegetables high in fiber.
- Avoid alcohol as it can further damage the liver.

2. **Hydration**:
- Drink plenty of water to help with overall liver function.

3. **Exercise**:
- Engage in regular, moderate exercise to support overall health and maintain a healthy weight.

4. **Medications**:
- Follow the prescribed medications to alleviating symptoms or underlying causes.

5. **Avoid Toxins**:
- Minimize exposure to chemicals and toxins that can strain the liver.

6. **Regular Monitoring**:
- Keep regular medical check-ups to monitor liver function and assess the condition.

Following these recommendations can help manage symptoms and support liver health in individuals with cholestasis.
Medication: For cholestasis, medication options may include:

1. **Ursodeoxycholic acid (UDCA):** Helps improve bile flow and reduce symptoms.
2. **Cholestyramine:** Used to alleviate itching associated with cholestasis.
3. **Rifampin:** An antibiotic that can also reduce itching.
4. **Naltrexone:** Sometimes used to relieve severe itching.
5. **Vitamin supplements:** Fat-soluble vitamins (A, D, E, K) may be needed due to malabsorption.

Treatment should always be guided by a healthcare professional.
Repurposable Drugs: Repurposable drugs for cholestasis that have shown potential include:

1. **Ursodeoxycholic Acid (UDCA):** Originally used for primary biliary cholangitis, it can improve bile flow and liver function.
2. **Rifampicin:** Known for its antibiotic properties, it can also reduce pruritus (itching) associated with cholestasis.
3. **Obeticholic Acid:** Originally approved for primary biliary cirrhosis, it may help reduce bile acid synthesis.
4. **Fibrates:** Drugs such as bezafibrate, typically used for lipid disorders, might improve bile flow and liver function.

Currently, there is no notable information on "nan" as it pertains to cholestasis. If "nan" refers to a specific term or abbreviation, additional context would be needed for a precise answer.
Metabolites: Cholestasis is a condition where bile flow from the liver is reduced or blocked. Metabolites that can be affected by this condition include bilirubin, bile acids, cholesterol, and various liver enzymes like alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT).
Nutraceuticals: There is no established evidence that supports nutraceuticals as a primary treatment for cholestasis. Nutraceuticals, which are food-derived products with potential health benefits, may be considered as adjuncts to conventional treatments. Commonly discussed nutraceuticals for liver health include milk thistle (silymarin), curcumin, and omega-3 fatty acids. However, their efficacy specifically for cholestasis remains unclear. Always consult a healthcare provider before starting any new supplement regimen for cholestasis.
Peptides: Cholestasis is a condition where bile flow from the liver is reduced or blocked. This can cause a buildup of bile acids in the liver and bloodstream, leading to liver damage and other complications.

**Peptides:** Peptides play an emerging role in the diagnosis and treatment of cholestasis. Bile acids themselves are key molecules in bile and are modified by peptide-like structures. Synthetic peptides and peptide-based drugs are being investigated to modulate bile acid receptors, improve bile flow, and reduce liver damage.

**Nan:** Nanotechnology offers promising diagnostic and therapeutic advancements for cholestasis. Nanoparticles can be used to deliver drugs directly to the liver, improving treatment efficacy and minimizing side effects. They may also be used in diagnostic imaging to provide more precise detection of bile duct obstructions and liver tissue changes.

Research in both peptides and nanotechnology continues to expand, potentially offering new and more effective ways to manage and treat cholestasis.